Programming

Joint Hypertension 2018 Scientific Sessions

AHA Council on Hypertension | AHA Council on Kidney in Cardiovascular Disease
American Society of Hypertension

September 6–9, 2018
Hyatt Regency Chicago | Chicago, Ill.
Registration Information
Take advantage of Early Registration prices through July 6, 2018.


See more Registration and Housing information.
Abstract Submission
Late-Breaking Abstracts open May 11, 2018 at 8:00 a.m. CST


See Late-Breaking Abstract Categories & Submission Guidelines (PDF)

Schedule

Download a printable copy of this Schedule-at-a-glance (PDF) or click on each day to see details below:

Click on a day/date to expand or collapse

#Hypertension18 Thursday, Sept. 6
TIMEACTIVITY
7:00 – 7:45 a.m.Coffee & Exhbits
7:45 – 8:00 a.m.President's Welcome
Ivor Benjamin, MD, FAHA
8:00 – 10:00 a.m.Session 1: Opening Remarks and Lectures
Highlights of the New Hypertension Guidelines – Jan Basile, MD, F.A.S.H.
Implementation of the New Hypertension Guidelines – Brent Egan, MD
Clinical Hypertension Research: Where Do We Go From Here? – Suzanne Oparil, MD
Recent Advances and Future Directions in Basic Research – David Ellison, MD
10:00 – 10:30 a.m.Refreshment Break
10:30 – 11:10 a.m.Session 2: Lifestyle Modifications and Impact on BP
Optimizing Cardiometabolic Health – Robert J. Chilton, MD
The Anti-Aging Effects of Aerobic Exercise on Systemic Arteries – Hirofumi Tanaka, PhD
11:10 – 12:00 p.m.Obesity and Cardiovascular Disease
Obesity Paradox in Hypertension: Should the SNS Be a Target to Improve Cardiometabolic Risk? – Elisabeth Lambert
Cardiovascular Disease and Obesity: Recent Advances and Future Directions – John Hall, PhD
12:00 – 1:30 p.m.Lunch on Your Own
1:30 – 3:00 p.m.Concurrent Session 4
A
– Inflammation, Immunity & Cytokines
B – Asian Pacific Symposium on Cardiovascular Research
C – Renin Angiotension System I
1:30 – 3:00 p.m.Concurrent Session 5
D
– Clinical Practice Clinical Science Track
3:00 – 3:30 p.m.Refreshment Break
3:30 – 5:30 p.m.Concurrent Session 5
A
– Obesity and Diabetes I
B – Cardiac Hypertrophy and Dysfunction
C – Pregnancy and Preeclampsia
3:30 – 5:30 p.m.Concurrent Session 5
D
– Clinical Practice Clinical Science Track
6:00 – 7:00 p.m.POSTER SESSION I
Trainee Onsite Poster Competition with Reception

#Hypertension18 Friday, Sept. 7
TIMEACTIVITY
7:00 – 8:00 a.m.Coffee and Exhibits
8:00 – 9:00 a.m.Session 6: Debate – Renal Denervation: Is There a Role in Essential Hypertension?
Pro: Ray Townsend, MD
Con: George Bakris, MD
9:00 – 10:00 a.m.Session 7: Hot Topics in Hypertension
Epigenetic Determinants of Cardiovascular Gene Expression: Vascular Endothelium – Phil Marsden, MD
Sex Differences in Mechanisms of Hypertension Association with Obesity – Eric Belin de Chantemele, D.SC
10:00 – 10:30 a.m.Refreshment Break
10:30 – 11:15 a.m.Session 8: Hypertension, Cardiac Hypertrophy, and Heart Failure
The Progression from Hypertension to Congestive Heart Failure in Patients: How Do We Stop It? – Daniel Levy, MD
Inhibition of Hypertrophy is a Good Therapeutic Strategy in Ventricular Pressure Overload – TBD
11:15 – 12:00 p.m.Session 9: Blood Pressure and Neurocognition
Will the New Guidelines Effect Cognition in Adults? – Jeff Williamson, MD
BP and Cognition in Children and Adolescents – Marc Lande, MD, MPH
12:00 – 1:30 p.m.Lunch on Your Own
1:30 – 3:00 p.m.POSTER SESSION II
1:30 – 3:00 p.m.Session 10: Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines, Part 1
Welcome and Introduction to Primary Care Track: Goals and Objectives
What do the 2017 ACC/AHA Guidelines Actually Say?
Understanding the Data that Drove the 2017 ACC/AHA Guidelines
The Difference Between Blood Pressure Targets and Performance Measures: Brief Explanation of the Epidemiology of Achieved Blood Pressure
The American College of Physicians (ACP) and American Academy of Family Practice (AAFP) Perspective
Q&A
3:00 – 3:30 p.m.Refreshment Break
3:30 – 4:00 p.m.Arthur C. Corcoran Memorial Lecture
4:00 – 5:30 p.m.Concurrent Session 11
A
– Gender Differences and Sex Hormones
B – Hypertension Early Career Oral Awards Session
C – Aldosterone, Its Receptors, and Other Hormones
3:30 – 5:30 p.m.Concurrent Session 11: D – Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines Part 2: Areas of Controversy
Blood Pressure Goals in Diabetes and Chronic Kidney Disease
The Older Patient with Hypertension
Treating Hypertension in Low-Risk Individuals: How Long Do We Hold Off on Pharmacologic Treatment?
Can't We All Just Get Along? Finding Consensus Among Guidelines and Statements
Case Based Discussion Panel on Areas of Controversy in the Guidelines
Q&A
5:30 – 5:45 p.m.Refreshment Break
5:45 – 6:45 p.m.Session 12: Awards Session
Mid-Career Award
Harry Goldblatt Award
British Hypertension Society Young Investigator Award
High Blood Pressure Research Council of Australia Award
7:00 – 11:00 p.m.Trainee Advocacy Mixer

Hypertension18 Saturday Sept 8
TIMEACTIVITY
6:30 – 7:30 a.m.Coffee and Exhibits
7:30 – 8:00 a.m.Donald Seldin Award Lecture
8:00 – 9:30 a.m.Concurrent Session 13
A – Vascular Biology and Dysfunction
B – Renal Vascular Function in Health and Disease
C – Hypertension Journal Case Studies
7:30 – 9:30 a.m.Concurrent Session 13:
D – Primary Care Track: Emerging Issues in Hypertension Management

How Do Environmental Factors Effect Blood Pressure?
Treatment of Hypertension in the Women Considering Conception
Remote Monitoring and Patient Self-Management - Is it the Future of BP Management?
Management of Hyper-and-Hypo-Kalemia in Treated Hypertensive Patients
Surgical and Percutaneous Interventions in Management of Hypertension
Q&A
9:30 – 10:00 a.m.Refreshment Break
10:00 – 10:30 a.m.Harriet Dustan Award Lecture
10:30 – 12:00 p.m.Concurrent Session 14
A – Blood Pressure Monitoring
B – Obesity and Diabetes II
C – Neurogenic Mechanisms I
10:00 – 12:00 p.m.Concurrent Session 14
D – Primary Care Track: The Evolving Landscape of Blood Pressure Guidelines Part 3: Special Situations
Determining Adequacy of BP Control: Using Appropriate Technique and Integrating In and Out of Office Measurements
Management of Resistant Hypertension: Have We Learned Anything New?
Implementation of Pediatric Guidelines for Hypertension Management
Q&A
Case 1: Presented by Local PCP
Case 2: Presented by Local PCP
12:00 – 1:30 p.m.Awards Luncheon and Business MeetingTickets Required
1:30 – 3:00 p.m.POSTER SESSION III
1:30 – 3:00 p.m.Clinical Practice Clinical Science Track
3:00 – 3:30 p.m.Refreshment Break
3:30 – 5:30 p.m.Concurrent Session 16
A – Blood Pressure Control and Adherence to Treatment
B – Salt and Hypertension
C – The Kidney: Causes and Consequences of Hypertension
3:30 – 5:30 p.m.Concurrent Session 16
D – Clinical Practice Clinical Science Track
5:45 – 6:30 p.m.The Excellence Award for Hypertension Research
7:30 – 8:00 p.m.Excellence Award for Hypertension Research Reception
8:00 – 10:00 p.m.Excellence Award for Hypertension Research Dinner

Hypertension18 Sunday, Sept 9
TIMEACTIVITY
6:30 – 7:30 a.m.Coffee and Exhibits
7:30 – 8:00 a.m.Dahl Award Lecture
8:00 – 9:30 a.m.Concurrent Session 18
A
– Neurogenic Mechanisms II
B – Vascular Stiffness
C – Epidemiology
7:30 – 9:30 a.m.Concurrent Session 18
D – Clinical Practice Clinical Science Track
9:30 – 10:00 a.m.Refreshment Break
10:00 – 11:30 a.m.Concurrent Session 19
A – Salt Sensitive Hypertension
B – Renin-Angiotensin System II
C – Developmental Programming and Pregnancy-Induced Hypertension
10:00 – 11:30 a.m.Concurrent Session 19
D – Clinical Practice Clinical Science Track
11:00 a.m.Meeting Adjourns

About This Meeting

AHA’s Hypertension 2018 Scientific Sessions, focusing on recent advances in basic and clinical research on hypertension, is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.

The planned agenda includes 18 sessions during 3½ days, with more than 500 presentations focused on recent advances in hypertension research including oral and poster presentations selected from abstracts submitted by clinical and basic researchers as well as the Primary Care and Clinical Practice Clinical Science Tracks for Clinicians.

Target Audience

The conference is designed to benefit research scientists, clinicians, and other healthcare professionals in the fields of hypertension research, cardiology, nephrology, endocrinology and related disciplines.

Learning Objectives

  1. Discuss changes to the AHA/ACC guidelines for the management of hypertension and their clinical implications.
     
  2. Describe opportunities to improve blood pressure measurement in the clinical setting to provide more accurate results.
     
  3. Identify immune and inflammatory mechanisms that contribute to the development of hypertension and hypertension-related end-organ damage and discuss the research and clinical implications.
     
  4. Educate participants about medical approaches for the management of comorbid obesity in patients with hypertension.
     
  5. Describe new and emerging strategies for treating resistant hypertension.
     
  6. Describe participants on the impact of value-based reimbursement on hypertension management and identify opportunities to improve its management.